15.0 Referenzen
1) Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
2) Nerich V, Monnet E, Etienne A, Louafi S, Ramee C, Rican S, Weill A, Vallier N,Vanbockstael V, Auleley GR, Allemand H, Carbonnel F. Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis 2006;12:218-26.
3) Rath HC, Andus T, Caesar I, Scholmerich J. Initial symptoms, extra-intestinal manifestations and course of pregnancy in chronic inflammatory bowel diseases. Med Klin (Munich). 1998;93:395-400.
4) Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W; European Crohn's and Colitis Organisation, European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1-15.
5) Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis 2007;13:225-34.
6) Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-23.
7) Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000279.
8) Moser G. Should we incorporate psychological care into the management of IBD? Nat Clin Pract Gastroenterol Hepatol. 2006;3:416-7.
9) Maxwell S, Zuckerman S, Berenson RA. Use of physician’s services under Medicare’s resource-based payments. N Engl J Med 2007;356:1853-61.
10) www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-de.pdf.
11) Stark R., König H.-H., Leidl R., Costs of Inflammatory Bowel Disease in Germany. Pharmacoeconomics 2006;24:797-814.
12) Bodger K., Cost of Illness of Crohn’s Disease. Pharmacoeconomics 2002;20:639-52.
|
English version
Impressum
Sitemap
Kontakt
Letzte Aktualisierung: 08.06.2007 durch Franz Schiener
